RICOLINOSTAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H27N5O3
Molecular Weight	433.5029
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=QGZYDVAGYRLSKP-UHFFFAOYSA-N

InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)

HIDE SMILES / InChI

Description
Sources: http://www.acetylon.com/docs/ACE-MM-101_Poster_Final%20Draft.pdf

Ricolinostat is a selective inhibitor of HDAC6 with IC50 value of 4.7 nM. Ricolinostat demonstrated good anti-proliferative activity on different cell lines and clinical models of cancer. The drug is being tested in phase I/II for the treatment of multiple myeloma and lymphoid malignancies and in phase I in patients with breast cancer, gynecological cancer, cholangiocarcinoma, recurrent chronic lymphoid leukemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histone deacetylase 6 27 Target ID: CHEMBL1865 Sources: http://www.acetylon.com/docs/ACE-MM-101_Poster_Final%20Draft.pdf	Inhibitor 8297		4.7 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Multiple myeloma 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27646843	Primary	Phase II 1132	Unknown Approved Use Unknown
Lymphoid malignancies 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02091063	Primary	Phase II 1132	Unknown Approved Use Unknown
Recurrent chronic lymphoid leukemia 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02787369	Primary	Phase I 428	Unknown Approved Use Unknown
Gynecological cancer 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02661815	Primary	Phase I 428	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://clinicaltrials.gov/ct2/show/NCT02632071	Primary	Phase I 428	Unknown Approved Use Unknown
Cholangiocarcinoma 17 Sources: https://clinicaltrials.gov/ct2/show/NCT02856568	Primary	Phase I 428	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P000ZZB	https://www.1pchem.com/search?query=1P000ZZB
AChemBlock	R16029	http://www.achemblock.com/catalogsearch/result/?q=R16029
AK Scientific	X5832	https://aksci.com/item_detail.php?cat=X5832
Ambeed	A173859	http://www.ambeed.com/search/Search.html?keyword=A173859
Angene	AGN-PC-09QXLN	http://www.angenechemical.com/productshow/AGN-PC-09QXLN.html
ApexBio Technology	A4083	https://www.apexbt.com/catalogsearch/result/?q=A4083
AstaTech	44004	http://astatechinc.com/CPSResult.php?CRNO=44004
BOC Sciences	1316214-52-4	http://www.bocsci.com/description.asp?cas=1316214-52-4
Cayman Chemical	21531	http://www.caymanchem.com/app/template/Product.vm/catalog/21531
Chem Scene	CS-0965	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0965
ChemShuttle	109813	https://www.chemshuttle.com/catalogsearch/result/?q=109813
Combi-Blocks	QJ-1082	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-1082
Excenen	EX-A139	http://www.excenen.com/searchresultlist.php?id=EX-A139
Hairui	HR117373	http://www.hairuichem.com/en/product/search.do?q=HR117373
KeyOrganics	AS-73344	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-73344
Matrix Scientific	146698	http://www.matrixscientific.com/146698.html
MedChem Express	HY-16026	https://www.medchemexpress.com/search.html?q=HY-16026&ft=&fa=&fp=
MolPort	MolPort-028-600-031	https://www.molport.com/shop/molecule-link/MolPort-028-600-031
Molnova	M11280	https://www.molnova.com/en/serch-list.html?keywords=M11280
MuseChem	I001219	https://www.musechem.com/product/I001219.html
Selleck Chemicals	S8001	http://www.selleckchem.com/search.html?searchDTO.searchParam=S8001
ShangHai Biochempartner	BCP000655	http://www.biochempartner.com/search_BCP000655
ShangHai Biochempartner	BCP06028	http://www.biochempartner.com/search_BCP06028
TargetMol	T2489	https://www.targetmol.com/search?keyword=T2489
Toronto Research Chemicals	A617440	https://www.trc-canada.com/product-detail/?CatNum=A617440
Toronto Research Chemicals	D486990	https://www.trc-canada.com/product-detail/?CatNum=D486990
eMolecules	44786334	https://orderbb.emolecules.com/search/#?query=44786334
eNovation Chemicals	D320040	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D320040&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-8807105455	https://mcule.com/MCULE-8807105455/

PubMed

Title	Date	PubMed
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.	2012 Mar 15	22262760
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.	2013 Aug 22	23627282

Patents

Sample Use Guides

In Vivo Use Guide

Lymphoid Malignancies: Patients take 160 mg for 28 consecutive days on a 28-day treatment cycle. Multiple myeloma: Patients take 40-240 mg once daily to 160 mg twice daily

Route of Administration: Oral

In Vitro Use Guide

MCF-7, MDA-MB-436, MDA-MB-231, T47D, SUM-190, IBC-3, SUM-149 cell lines were treated with increasing concentrations of ricolinostat (1, 2.5, 5 uM) to test drug-induced apoptosis.

Name

Type

Language

RICOLINOSTAT

Official Name

English

ricolinostat [INN]

Common Name

English

5-PYRIMIDINECARBOXAMIDE, 2-(DIPHENYLAMINO)-N-(7-(HYDROXYAMINO)-7-OXOHEPTYL)-

Systematic Name

English

Ricolinostat [WHO-DD]

Common Name

English

ACY-1215

Code

English

RICOLINOSTAT [USAN]

Common Name

English

2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide

Systematic Name

English

ACY-63

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1946